Somatrogon, sold under the brand name Ngenla, is a medication for the treatment of growth hormone deficiency.
[6] The most common side effects include reactions at the site of injection, headache, and fever.
[7] Somatrogon was approved for medical use in Australia in November 2021,[1] in the European Union in February 2022,[7] and in the United States in June 2023.
[6][9] The US Food and Drug Administration (FDA) approved somatrogon based on one clinical trial (NCT02968004) of 224 children with growth hormone deficiency and short stature.
[9] The trial was conducted at 84 sites in 24 countries including Argentina, Australia, Bulgaria, Belarus, Canada, Colombia, Germany, Georgia, Greece, India, Israel, Italy, Mexico, New Zealand, Poland, South Korea, Russia, Spain, Taiwan, Turkey, Ukraine, the United Kingdom, Vietnam, and the United States.